Compare AFLAC Incorporated (AFL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs ResMed Inc. — how do they compare? AFLAC Incorporated trades at $120.6 (market cap $60.70B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: AFLAC Incorporated is the larger of the two by market cap, and AFLAC Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AFL | RMD | |
|---|---|---|
Market Cap | $60.70B | $32.61B |
Sector | Financials | Health |
52-Week High | $129.55 | $293.73 |
52-Week Low | $103.55 | $182.82 |
Enterprise Value | $70.65B | $31.97B |
Dividend Yield | 2.02% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $120.98, down 0.79% on the day, with a P/E of 13.06 and net income margin of 26.59%. Recent earnings missed estimates for three consecutive quarters, with Q3 2026 results pending. Technical indicators show a bullish overall signal despite bearish moving averages and oscillators. The company maintains a strong dividend history, with recent payouts of $0.61 per share.
Outlook remains mixed; solid profitability and dividend growth support income investors, but earnings misses and revenue declines pose near-term risks. Analyst consensus is cautious with a hold-heavy rating and price target of $118, slightly below current levels. Key catalysts include U.S. sales momentum and Japan unit performance, while currency headwinds and medical cost inflation are concerns.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
